The independent source for health policy research, polling, and news.
621 - 640 of 703 Results
Two Democratic congressmen met with President Trump to seek his support for a bill to expand the government鈥檚 ability to negotiate drug prices, but it鈥檚 not clear it would have much impact or will gain support.
Amid an uproar over high drug prices, three GOP senators are asking the Government Accountability Office to investigate whether the Orphan Drug Act is being abused.
A new study shows that 83 percent of the largest patient advocacy groups take contributions from drug, medical device or biotech firms.
A drug from Marathon Pharmaceuticals has ignited a firestorm on Capitol Hill and beyond. What makes it different than the $750,000 drug that came before it?
Former FDA Commissioner Dr. Robert Califf shares his views about drug approvals, regulations and safety concerns after stepping down from the giant agency.
After hearing complaints about its high price, Marathon Pharmaceuticals is pausing the launch of an $89,000 drug for a rare disease.
Citing a Kaiser Health News investigation, Senate Judiciary Committee Chairman Chuck Grassley vows to examine the orphan drug program and possible fixes.
Kaiser Health News reporter Shefali Luthra discusses the controversy surrounding Kaleo, a company that makes a life-saving auto-injector for opioid drug overdoses on Weekend Edition.
Wood, who chairs the Assembly Health Committee, lays out his priorities for 2017.
Orphan drugs for rare diseases have helped or saved hundreds of thousands of patients like 2-year-old Luke Whitbeck, but families and insurers are picking up the astronomical cost.
Drugmakers have brought almost 450 orphan drugs to market and collected rich incentives but nearly a third of those products aren鈥檛 new or were repurposed multiple times, an investigation shows.
Follow the twists and turns of the orphan drug industry over the past three decades.
Check out all the drugs the FDA has approved to treat rare diseases. You can search by brand name, or by disease, and see familiar names that were first sold on the mass market or all the drugs that won FDA approval to treat more than one rare disease.
The former Congressman championed the Orphan Drug Act decades ago but now he fears it鈥檚 being manipulated to make money.
The federal government pays for kidney transplants. But the program only pays for essential anti-rejection drugs for three years. Many people can't afford them and can end up losing the kidney.
Investigators claim drugmaker employees met in secret at restaurants, golf outings and at 鈥淕irls Night Out鈥 to raise generic drug prices.
Eight percent of those polled by the Kaiser Family Foundation say they have purchased medications outside of the U.S. to save money.
Advocates want alternatives to drugmaker's pricey pills for those who choose to die in Colorado and elsewhere.
Three lobbyists for every member of Congress in a push to pass a bill that increases research funding and speeds up approvals.
The legislation would give federal officials more flexibility in evaluating the effectiveness and safety of drugs and devices and add billions of dollars to NIH funding. But critics say it could endanger patients鈥 safety and doesn鈥檛 do enough to stop spiraling drug prices.
漏 2026 KFF